The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
NATERA, INC. | COM | 632307104 | 3,577,764 | 64,441 | SH | SOLE | 0 | 0 | 64,441 | ||
UNITY BIOTECHNOLOGY, INC. | COM | 91381U200 | 1,637,852 | 1,004,817 | SH | SOLE | 0 | 0 | 1,004,817 | ||
DENALI THERAPEUTICS, INC. | COM | 24823R105 | 59,183,977 | 2,568,749 | SH | SOLE | 0 | 0 | 2,568,749 | ||
KARUNA THERAPEUTICS, INC. | COM | 48576A100 | 5,449,200 | 30,000 | SH | SOLE | 0 | 0 | 30,000 | ||
SINGULAR GENOMICS SYSTEMS, INC. | COM | 82933R100 | 4,596,700 | 3,798,926 | SH | SOLE | 0 | 0 | 3,798,926 | ||
EQRX, INC. | COM | 26886C107 | 70,490,628 | 36,335,375 | SH | SOLE | 0 | 0 | 36,335,375 | ||
ERASCA, INC. | COM | 29479A108 | 33,277,218 | 11,055,554 | SH | SOLE | 0 | 0 | 11,055,554 | ||
VERVE THERAPEUTICS, INC. | COM | 92539P101 | 28,967,026 | 2,008,809 | SH | SOLE | 0 | 0 | 2,008,809 |